Article
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Clinical pharmacology and therapeutics - 1 Jul 2008
Ufer M, Dilger K, Leschhorn L, Daufresne Lm, Mosyagin I, Rosenstiel P, Haesler R, Kuehbacher T, Nikolaus S, Schreiber S, Cascorbi I
Abstract excerpt
Budesonide treatment of chronic inflammatory bowel disease commonly leads to non-response or adverse reactions, possibly because of alterations in efflux transport mediated by the ABCB1 gene product P-glycoprotein or metabolism by CYP3A isoenzymes. Two groups, each consisting of nine healthy volunteers, one with the CYP3A5(*)1/(*)3 genotype (expressors) and the other with the CYP3A5(*)3/(*)3 genotype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.